Search results
Results from the WOW.Com Content Network
The Journal of the National Comprehensive Cancer Network, established in 2003, is a monthly peer-reviewed medical journal of oncology and the official journal of the National Comprehensive Cancer Network (NCCN). It is published by Harborside Press and the editor-in-chief is Margaret Tempero (UCSF Helen Diller Family Comprehensive Cancer Center ...
The NCCN recommends the use of the same AJCC-UICC staging system as pancreatic adenocarcinoma. [10]: 52 Using this scheme, the stage by stage outcomes for PanNETs are dissimilar to pancreatic exocrine cancers. [23] A different TNM system for PanNETs has been proposed by The European Neuroendocrine Tumor Society. [24]
An advantage is the cosmetic result: after treatment, the skin resembles normal skin without the usual scarring and morbidity associated with standard excision. Imiquimod is not FDA-approved for any squamous-cell carcinoma. In general, squamous-cell carcinomas have a high risk of local recurrence, and up to 50% do recur. [60]
The National Comprehensive Cancer Network (NCCN) is an alliance of 33 [1] cancer centers in the United States, most of which are designated by the National Cancer Institute (one of the U.S. National Institutes of Health) as comprehensive cancer centers. It is a non-profit organization with offices in Plymouth Meeting, Pennsylvania.
The 2021 U.S. Preventive Services Task Force guidelines recommend annual screening for lung cancer with low-dose computed tomography in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. [6]
The National Comprehensive Cancer Network (NCCN) guidelines recommend bilateral prophylactic mastectomy and bilateral salpingo-oophorectomy for women who are carriers of germline BRCA1/2 mutation. At the age of 35 to 40 years, or once childbearing is completed, the procedure is recommended for risk reduction purposes.
The reason given is: Per the 2021 update of the WHO classification, almost any oligoastrocytoma can be classified as either astrocytoma or oligodendroglioma via genetic testing. Oligoastrocytoma is reserved for tumors with incomplete diagnostics. Please help update this article to reflect recent events or newly available information. (August 2021)
In March 2021, trilaciclib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) as an appropriate prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression for patients undergoing chemotherapy for extensive-stage small-cell lung cancer. [16]